Strategic partnerships Iovance is actively expanding through collaborations with health systems, such as Community Health Network in Indiana, positioning the company to accelerate TIL therapy adoption and generate pathway opportunities with integrated care networks.

Product expansion Beyond Lifileucel, Iovance is developing Amtagvi for endometrial cancer, signaling a broader product slate that could create additional CRO, manufacturing, and payer opportunities across multiple tumor indications.

Commercial readiness The company is executing a commercial launch while building internal manufacturing capabilities at the iCTC and expanding research sites, presenting upsell potential for service contracts, supply chain partnerships, and scale-ready collaborations with biopharma and hospitals.

Competitive positioning As a leading TIL therapy innovator with a large funding base and ongoing clinical data across solid tumors, Iovance presents a compelling partner for health systems seeking differentiated cell therapy portfolios and early access to cutting-edge therapies.

Financial and risk landscape With substantial funding and a Class Action exposure, there are diligence touchpoints for partners and investors around risk management, regulatory timelines, and long-term durability of manufacturing capabilities, informing co-development and joint venture structuring opportunities.